March 27, 2023
RegMed Investors’ (RMi) closing bell: a BUY zone or just another algorithm rebound?
March 24, 2023
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector reversed losses to close positive
March 23, 2023
RegMed Investors’ (RMi) closing bell: momentum interrupts sector’s share pricing bouncing luckily to the upside
March 22, 2023
RegMed Investors’ (RMi) closing bell: more push and pull-down share pricings
March 21, 2023
RegMed Investors’ (RMi) closing bell: an upside after negative actions
March 20, 2023
RegMed Investors’ (RMi) closing bell: cell and gene therapy equities are back in the trenches with share pricing hunkering down
March 17, 2023
RegMed Investors’ (RMi) closing bell: a second Black Swan event this week
March 16, 2023
RegMed Investors’ (RMi) closing bell: sector responds to being oversold reversing some declines
March 15, 2023
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector suffers from Autophobia
March 13, 2023
RegMed Investors’ (RMi) closing bell: sector equities turn up from being oversold clouded by SVB’s decline
March 10, 2023
RegMed Investors’ (RMi) closing bell: bad goes to worse and fear for cell and gene therapy sector cash positions
March 9, 2023
RegMed Investors’ (RMi) closing bell: the sector does the limbo dance and low it went?
March 8, 2023
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector opened down, climbed up and then fell back
March 7, 2023
RegMed Investors’ (RMi) closing bell: indexes sell-off after Jerome spoke
March 6, 2023
RegMed Investors’ (RMi) closing bell: sector share pricing evaporated as upcoming Fed policy stymies share pricing
March 3, 2023
RegMed Investors’ (RMi) closing bell: sector gets a push pull
March 2, 2023
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector’s feeling the lack of sentiment
March 1, 2023
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector slumps after mid-day
February 28, 2023
RegMed Investors’ (RMi) closing bell: a volatile February comes to an end as Q4 and FY22 keep rolling out
February 27, 2023
RegMed Investors’ (RMi) closing bell: hunker down but, be aware of earnings backlash
February 22, 2023
RegMed Investors’ (RMi) closing bell: the sector’s continuous menace - sustainability
February 21, 2023
RegMed Investors’ (RMi) closing bell: extending losses as fear defines the cell/gene therapy sector with Q4 and FY22 earnings release bringing more pressures
February 17, 2023
RegMed Investors’ (RMi) closing bell: a concluding weekly reverse as the oversold sector was recognized closing positive after a bad morning
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.